Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead 
Welcome,         Profile    Billing    Logout  
 50 Diseases   11 Trials   11 Trials   833 News 


«123456789101112»
  • ||||||||||  Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
    Journal:  Hydroxysafflor Yellow A Together with Blood-Brain Barrier Regulator Lexiscan for Cerebral Ischemia Reperfusion Injury Treatment. (Pubmed Central) -  Aug 11, 2020   
    Lastly, HSYA together with Lex (Lex-HSYA) could significantly reduce the volume of cerebral infarction, improve the histopathological morphology, and recruit brain-derived neurotrophic factors to alleviate the cerebral ischemia reperfusion injury. In conclusion, the pyroptosis pathway could act as a novel therapeutic target of HSYA in nerve injury treatment, and Lex-HSYA could be a promising candidate for nerve injury treatments.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Enrollment change, Trial completion date, Trial primary completion date:  Allograft Dysfunction in Heart Transplant (clinicaltrials.gov) -  Aug 8, 2020   
    P4,  N=376, Recruiting, 
    In conclusion, the pyroptosis pathway could act as a novel therapeutic target of HSYA in nerve injury treatment, and Lex-HSYA could be a promising candidate for nerve injury treatments. N=36 --> 376 | Trial completion date: Apr 2020 --> Apr 2024 | Trial primary completion date: Apr 2020 --> Apr 2024
  • ||||||||||  Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
    [VIRTUAL] The imortance of hyperemic contrast velocity assessment on image-based fractional flow reserve calculation () -  Jul 30, 2020 - Abstract #ESC2020ESC_1647;    
    Significantly higher AUC were detected by the hyp FFRsim than by the rest FFRsim: 0.936 (95% CI: 0.828 to 0.985) vs. 0.862 (CI: 0.734 to 0.943); p= 0.011.Linear regression analyses between the FFRsim (either by fixed FFRsim or by rest FFRsim or by hyp FFRsim methods) and the FFRmeas showed higher intercepts and less steep of the slopes in the subgroups with presence of microvascular disease defined as CFRFC/FFRmeas 2); the difference reached significant level (p=0.019) when calculated by rest FFRsim. Conclusions Hyperemic challenge either by adenosine or regadenoson is required for exact image-based FFR calculation especially in cases of suspicion for microvascular coronary disease.
  • ||||||||||  acetazolamide / Generic mfg., aspirin / Generic mfg., Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
    [VIRTUAL] Coronary microvascular function is impaired in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) () -  Jul 30, 2020 - Abstract #ESC2020ESC_1279;    
    Seventeen patients with genetically-confirmed CADASIL, aged <60 years, with ≤1 cardiovascular risk factor (current smoke, diabetes, hypertension, dyslipidemia), recent (<3 months) neurological evaluation with neuropsychological tests and 3 Tesla brain magnetic resonance imaging (MRI) underwent 12-lead ECG, echocardiography, and measurement of maximal myocardial blood flow following Regadenoson infusion (Reg-MBF) by 13NH3positron emission tomography (PET), to investigate the presence of coronary microvascular dysfunction (CMD)...One was a current smoker and 3 ex-smokers; 1 patient was on aspirin, 1 on acetazolamide and 2 on escitalopram, none was taking statins...These data represent the first documentation of coronary microvascular involvement in a group of young and mildly symptomatic CADASIL patients, confirming the systemic nature of the disease. This proof of concept study expands our understanding of genetically-driven CMD.
  • ||||||||||  hydroxyurea / Generic mfg., Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead, AT-1226 / Ahead Therap
    [VIRTUAL] An Unusual Case of Acute Myocardial Infarction Revealing Underlying Polycythemia Secondary to Exogenous Bioidentical Testosterone Therapy () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_774;    
    Compound pharmacies providing bioidentical testosterone are not required to report adverse events, provide black box warnings, or show evidence-based safety and efficacy profiles for their products. The increasing availability and use of non-FDA-approved testosterone therapies warrants increased physician vigilance, particularly for patients with existing cardiac conditions or predisposition to hypercoagulable and prothrombotic states.
  • ||||||||||  Cangrelor (ARC69931MX) / Novartis, Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead, Effient (prasugrel) / Eli Lilly, Daiichi Sankyo
    Journal:  Adenosine Receptor Agonists Exhibit Anti-Platelet Effects and the Potential to Overcome Resistance to P2Y Receptor Antagonists. (Pubmed Central) -  May 29, 2020   
    Importantly, their inhibitory effects in combination with P2Y antagonists were similar in high- and low-responders to P2Y inhibitors. In conclusion, a combination of anti-platelet agents acting via the P1 and P2 purinergic receptors represents a promising alternative to existing antithrombotic therapy.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial primary completion date:  Heart Rate Response to Regadenoson and Sudden Cardiac Death (clinicaltrials.gov) -  May 27, 2020   
    P=N/A,  N=90, Active, not recruiting, 
    In conclusion, a combination of anti-platelet agents acting via the P1 and P2 purinergic receptors represents a promising alternative to existing antithrombotic therapy. Trial primary completion date: Jan 2020 --> Apr 2020
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal:  Autocatalytic Delivery of Brain Tumor-targeting, Size-shrinkable Nanoparticles for Treatment of Breast Cancer Brain Metastases. (Pubmed Central) -  May 24, 2020   
    We demonstrate that the integration of tumor responsiveness, tumor targeting, and BBB penetration enables LANPs to penetrate metastatic lesions in the brain with high efficiency, and, when doxorubicin was encapsulated, LANPs effectively inhibited tumor growth and prolonged the survival of tumor-bearing mice. Due to their high efficiency in penetrating the BBB for BCBMs treatment, LANPs have the potential to be translated into clinical applications for improved treatment of patients with BCBMs.
  • ||||||||||  Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
    Clinical, Journal:  P1 Receptor Agonists/Antagonists in Clinical Trials - Potential Drug Candidates of the Future. (Pubmed Central) -  May 1, 2020   
    Recruiting --> Active, not recruiting This review is an attempt to highlight the current status, progress and probable future of P1 receptor ligands which are under clinical trials as promising novel therapeutic agents and the direction in which research should proceed with a view to come out with novel therapeutic agents.
  • ||||||||||  dipyridamole / Generic mfg., Doburan (dobutamine) / VHB Life Sciences, Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
    Journal:  Myocardial Perfusion SPECT 2018 in Germany: Results of the 8th Survey. (Pubmed Central) -  Apr 28, 2020   
     The 2018 MPS survey reveals a high-grade adherence of routine MPS practice to current guidelines. The positive development in MPS performance and MPS numbers observed since 2012 remains ongoing.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead, NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  HFpEF-PRoF: Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF (clinicaltrials.gov) -  Apr 10, 2020   
    P4,  N=55, Completed, 
    Patients with high HbA1C level had significantly lower MBF, suggesting that glycemic control may have an important role in prevention of CAV. Recruiting --> Completed | Trial completion date: Aug 2020 --> Jan 2020 | Trial primary completion date: May 2020 --> Jan 2020
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Enrollment closed:  ArmCrank: Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome (clinicaltrials.gov) -  Apr 6, 2020   
    P=N/A,  N=300, Active, not recruiting, 
    Recruiting --> Completed | Trial completion date: Aug 2020 --> Jan 2020 | Trial primary completion date: May 2020 --> Jan 2020 Recruiting --> Active, not recruiting
  • ||||||||||  hydroxyurea / Generic mfg., Lexiscan (regadenoson) / Astellas, GE Healthcare, AT-1226 / Ahead Therap
    An Unusual Case of Acute Myocardial Infarction Revealing Underlying Polycythemia Secondary to Exogenous Bioidentical Testosterone Therapy (ENDOExpo) -  Apr 1, 2020 - Abstract #ENDO2020ENDO_3802;    
    Compound pharmacies providing bioidentical testosterone are not required to report adverse events, provide black box warnings, or show evidence-based safety and efficacy profiles for their products. The increasing availability and use of non-FDA-approved testosterone therapies warrants increased physician vigilance, particularly for patients with existing cardiac conditions or predisposition to hypercoagulable and prothrombotic states.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion:  Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer (clinicaltrials.gov) -  Mar 26, 2020   
    P=N/A,  N=25, Completed, 
    The increasing availability and use of non-FDA-approved testosterone therapies warrants increased physician vigilance, particularly for patients with existing cardiac conditions or predisposition to hypercoagulable and prothrombotic states. Active, not recruiting --> Completed
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Enrollment closed, Enrollment change:  Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT (clinicaltrials.gov) -  Mar 4, 2020   
    P=N/A,  N=15, Active, not recruiting, 
    It has excellent agreement with CA angiography and aided decision-making to proceed with revascularization. Recruiting --> Active, not recruiting | N=30 --> 15
  • ||||||||||  dipyridamole / Generic mfg., Doburan (dobutamine) / VHB Life Sciences, Lexiscan (regadenoson) / Astellas
    Journal:  Theophylline and Caffeine as Alternatives During an Aminophylline Shortage. (Pubmed Central) -  Mar 2, 2020   
    Alternatives to aminophylline include theophylline and caffeine. It is important to efficiently identify alternatives during a drug shortage to maintain optimal patient outcomes.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion date, Trial primary completion date:  Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation (clinicaltrials.gov) -  Feb 23, 2020   
    P1,  N=21, Recruiting, 
    This study provides preliminary evidence that CEUS could detect blood flow changes consistent with SCD physiology. Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2020 --> Aug 2021
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Clinical, Journal:  Safety and prognostic value of regadenoson stress cardiovascular magnetic resonance imaging in heart transplant recipients. (Pubmed Central) -  Dec 23, 2019   
    Regadenoson stress CMR is safe and well tolerated in heart transplant recipients, with no incidence of sinus node dysfunction or high-degree atrioventricular block, including in the first two years after heart transplantation. An abnormal regadenoson stress CMR identifies heart transplant recipients at a higher risk for major adverse cardiovascular events.
  • ||||||||||  Lexiscan (regadenoson) / Astellas, GE Healthcare
    [VIRTUAL] ANTERIOR SPINAL CORD SYNDROME IN THE SETTING OF CARDIAC CATHETERIZATION (eAbstract Virtual Hall) -  Dec 22, 2019 - Abstract #ACC2020ACC_7234;    
    The reported incidence of paraplegia following coronary catheterization and CABG are 0.1% and 0.23%, respectfully. 3D CT models have shown collateral circulation from LIMA to ADA.